Official Statistics: Mefloquine (Larium) Prescribing in the UK Armed Forces: 12 September 2016 to 31 March 2026

Why It Matters

The trends illustrate how the MOD is prioritising service‑member safety while maintaining malaria protection, influencing future defence health policies and procurement decisions.

Key Takeaways

• Mefloquine prescriptions fell 68% over ten years
• Alternative prophylactics now cover 74% of deployments
• Adverse‑event reports dropped by 45% since 2016
• Policy change aligned with NATO health guidelines
• Data will guide next‑generation malaria‑prevention strategy

Pulse Analysis

Mefloquine, marketed as Larium, has long been a cornerstone of malaria prophylaxis for deployed troops, but its neuropsychiatric side‑effects have sparked controversy. In September 2016 the UK Ministry of Defence introduced a new prescribing policy that tightened eligibility criteria, mandated regular neuro‑cognitive screening, and encouraged the use of newer agents such as atovaquone‑proguanil and doxycycline. The recently released statistical bulletin, covering the period up to March 2026, quantifies the policy’s effect, showing a 68% reduction in mefloquine prescriptions and a corresponding rise in alternative regimens. This shift reflects a broader defence health strategy that balances efficacy with tolerability, ensuring personnel remain combat‑ready without compromising mental health.

The data also reveal a 45% drop in reported adverse events linked to mefloquine, underscoring the success of tighter monitoring and the move toward safer alternatives. By integrating electronic health records across service branches, the MOD could track prescription patterns in near‑real time, allowing rapid policy adjustments. These insights are valuable not only for the British forces but also for allied militaries grappling with similar malaria‑risk environments, as they illustrate how evidence‑based prescribing can reduce drug‑related morbidity while preserving disease protection.

Looking ahead, the Ministry plans to use the findings to refine its malaria‑prevention toolkit, potentially phasing out mefloquine entirely for low‑risk deployments. The statistical bulletin serves as a benchmark for future health‑policy evaluations, offering a transparent view of how drug‑utilisation trends evolve under regulatory pressure. For defence health officials, procurement officers, and medical researchers, the report provides actionable intelligence that can shape training, supply chain decisions, and international collaboration on force health protection.